⌕
Olema Oncology · OLMA · Nasdaq
Tenet 55 · Mixed
Compare
$7.56+0.53%At closeTenet 55 · Mixed
$7.56+0.04 (+0.53%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Olema Oncology (OLMA) Stock

Olema Oncology (OLMA) closed at $7.56 on Nov 13, 2026; its Tenet Score is 55 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$7.56
Nov 13, 2026
Market cap
$662.3M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
6.24 – 36.26
low → high
Tenet Score
55/100
Mixed · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Olema Oncology Inc. scores 55/100. Mixed. Strongest on value and financial health, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 55 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
83
Quality
11
Health
71
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityFHealthBGrowth—MomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
1.8×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−70%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
6.12
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Olema Oncology Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selecti…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 59 US ETFs · top wrappers by weightSee all ETFs holding OLMA →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Olema Oncology in?

Olema Oncology is in the Healthcare sector and the Drugs industry.

What is Olema Oncology's Tenet Score?

Olema Oncology's Tenet Score is 55 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.